ALPHAMAB-B and Suzhou ALPHAMAB-B signed a technology development contract
ALPHAMAB-B (09966.HK) announced related transactions and signed a technology development contract with Suzhou ALPHAMAB. According to this, Suzhou ALPHAMAB is commissioned to provide technology development services, with a service fee of RMB 10.24 million. The company will develop production processes and analytical methods for bispecific antibody conjugate drug candidates, conduct sample preparation for toxicology studies and new drug clinical trial "IND" application clinical sample preparation, carry out quality and stability studies on related samples, and assist in IND registration application
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments